List of Peptide Therapies Companies in South Korea - 8

Aston Sci., a clinical stage biopharmaceutical company that is currently focusing on clinical development of innovative medicines in oncology, immunology, and geriatrics, including therapeutic cancer vaccines. Aston Sci. is constantly listening to the changing needs of the patients and will continue to move forward to improve the lives of patients who suffer from cancer recurrence, metastasis, or side effects during cancer treatment.

Dong-A ST is a company established in March 2013 following the restructuring of the former Dong-A Pharmaceutical into a holding company. Our company focuses on the development and sale of specialized pharmaceuticals (ETC) and is dedicated to the philosophy of "Our company's social contribution is in new drug development." With state-of-the-art research facilities such as the Yongin Research Center established in 1977 and the completion of the Songdo Research Center in 2021, Dong-A ST has been striving for innovative global new drug development with excellent research and development capabilities. For many years, by consistently investing more than 10% of its revenue in R&D, we have successfully developed multiple proprietary novel drugs, including Stillen, Zydena, Motilitone, Sivextro, and Suganon/Sugamet.

Since 2008, GemVax & KAEL has operated as a cutting-edge research and development company developing proprietary peptide drug, GV1001, for treatment against various cancers and neurodegenerative disease including Alzheimer's disease and Progressive Supranuclear palsy. The fundamental driving purpose of our innovative pharmaceutical research is to facilitate significant improvements to human life through the introduction of advanced medical technology and innovation rooted in advanced scientific measures. At GemVax, we take pride in our proactive approach to medical research, and our progressive peptide-drug focused advancements have played a crucial role in the incessant global battle against incurable disease.

ImmunoForge is a biopharmaceutical company that specializes in developing targeted cancer agents for conditions like sarcopenia and rare mutations including BCR-ABL, T315I, RET, and FGFR4.

Kolon Pharmaceutical, Inc. was established in 1958 with a mission to contribute on happiness of mankind and social welfare by enhancing people’s quality of life and providing top medical service thru development of innovative drugs with its respect for life and health. Kolon Pharmaceutical is a subsidiary of Kolon group which is one of the biggest industrial conglomerates of Korea that has core business domains in pharmaceuticals, biotechnology, cutting-edge materials, fashion, construction, environment, trade and IT. Kolon group’s health business unit is composed of three subsidiaries and they are Kolon Pharmaceuticals, Kolon Life Science(biotechnology) and Kolon Wellcare(drug store business). Kolon Pharmaceutical developed many outstanding products like Bicogreen for constipation, cold remedy Comy syrup & tablet, anti-fungal drug Konitra and Tamsulo capsule for prostatism with its own technology and also co-developed Brexin tablet(β-Cyclodextrin Prioxicam), Remicut SR capsule(Emedastine difumarate) and Pransus syrup(Pranoprofen) with outstanding pharmaceutical companies like Chiesi, Hisamitsu and Organon since its establishment. Kolon Pharmaceutical is also expanding its global presence by exporting its quality products like Flavon(Ginko biloba ext.), Diverine(Gliclazide), Tavisin(Ofloxacin), Clovana(Diclofenac) and Turant(Acetylcysteine) to Vietnam, Pakistan, Yemen and many other Middle Eastern countries. Our continuous efforts led us to fruitful outcomes in significant areas of our business especially new molecule research, joint research, development of API, new formulation and combination new drug.

인류는 현재 주목할 만한 시대를 살고 있습니다. 우리의 수명은 길어졌으며 앞으로 더욱 더 길어질 것입니다. 여기서 우리는 한가지 질문을 가져봐야 합니다. “진정 늘어난 수명이 행복한 삶이 될 것인가?” 행복한 삶은 오래 사는 것만이 아니라 아름답고 건강하게 살아가는 것입니다. 올리패스는 행복의 새로운 문을 열고자 합니다. 우리는 이러한 기대를 충족시키기 위해 2006년부터 기존 약물의 한계를 극복한 PNA(Peptide Nucleic Acid) 플랫폼을 개발하는데 최선을 다해 오고 있습니다. 올리패스는 차세대 RNA 치료제 개발을 선도하는 생명과학 기업입니다. 모든 질병과 노화를 극복하기 위해서는 각각의 세포들이 건강하고 젊게 유지되어야 합니다. 이 믿음을 갖고 우리는 RNA 치료제 기술을 통해 삶의 질을 획기적으로 높이는 꿈에 다가가고 있습니다. 올리패스에서는 다양한 분야의 과학자들이 각각의 세포들을 치유하고 완전하게 할 수 있는 방법을 찾기 위해 끊임없이 노력하고 있습니다. OliPass PNA 플랫폼 기술을 통해 우리가 이루고자 하는 꿈은 최고의 기술을 저렴하게 널리 쓰일 수 있게 개발해 전 세계 모든 사람들이 의료비 걱정없이 행복하고 건강한 삶을 살 수 있게 하는 것입니다. We are living in remarkable times, in fact when you think about it, over the past 100 years the life expectancy around the globe has almost doubled and we continue, of course, to constantly hope for even greater longevity. But we need to ask ourselves, does this increased longevity lead to a happier life? We all agree that true happiness does not result from just living longer, but also from living well. At OliPass, our mission is to open the door to a new era of healthy and beautiful aging. Since 2006, OliPass has been committed to revolutionizing the life sciences and improving the quality of life. Our research is focused on developing a new generation of therapeutics using our novel PNA based technologies. Thanks to our dedicated team and their hard work, OliPass is now a leading biotech company with OliPass PNA Platform Technology and a growing presence throughout the globe. At OliPass, scientists from diverse fields are constantly working together to find the cures for all diseases. With our innovative OliPass PNA platform technology, our goal is to make the highest quality of science affordable and accessible, so that everyone around the world can enjoy a happy, healthy life. OliPass is dedicated to providing safe and feasible options for healthy aging.

Established in 1997, Peptron focuses on platform technology and clinical developments. Referred to as "Cozy-Cure," Peptron's highest priority is promoting and promising the best quality of life for patients with better treatment options, compliance, and price advantage. Peptron members' expertise in drug discovery and research, business development and strategic planning, drug delivery and formulation, GMP production, and Quality Control has helped develop peptide-based platform technology, SmartDepot™. SmartDepot™ brings the initial research process to the final medication development and successful commercialization phase with superior competitiveness. In line with proprietary technologies, we develop sustained-release (SR) medications to extend the release profile of the drug from weekly to monthly. Further, Peptron values global CDMO business. In the last few years, we have successfully formulated working with global companies with our in-depth expertise and resources. Peptron can work with you to achieve formulation development, regulatory approval and commercial manufacturing.

Wellmarker Bio is a spin-off company from Seoul Asan Medical Center(AMC), which is the largest and most renowned hospital in the Republic of Korea. We specialized in developing predictive biomarkers and first-in-class drugs through profound research know-hows and Research Institute that is comprised of Target discovery department, Drug discovery department, Medicinal chemistry department and CMC department.